Atara Biotherapeutics, Inc.: Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel) Commercialization Agreement with Pierre Fabre
Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines
Source: finanznachrichten.de